We are a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Enzons drug-development programs utilize two platforms - Customized PEGylation Linker Technology (Customized Linker Technology®) and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon currently has four compounds in human clinical development and multiple novel mRNA antagonists in preclinical research. Enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary Customized Linker Technology.
Enzon does not provide tax advice. Stockholders should consult with their own tax advisors regarding the specific tax treatment of the special dividend that they received from Enzon.
Recent Releases View all »
Apr 23, 2013
Dec 17, 2012
Nov 29, 2012